Harvard Pilgrim Health Care Home
  Learn more.
  Sign up for HPHConnect.
Medical Management
For Your Patient
News Center
Network Matters
Newsletter Archives
Newsletter Registration
Office Support
Provider Manual
Medicare Advantage
Research & Teaching
Resources & Links
Print    Text Size

Network Matters
News and Information for the
Harvard Pilgrim Health Care Network

April 2014

Tier Change for Omnitrope and Tev-Tropin 

Effective immediately, Harvard Pilgrim has moved our preferred growth hormone products, Omnitrope and Tev-Tropin, from Tier 2 (Tier 3 on a 4-Tier formulary) to Tier 1 (Tier 2 on a 4-tier formulary) for members in our commercial plans. As a result, members who use these medications will be subject to a lower copayment.

Harvard Pilgrim requires prior authorization for all growth hormone products, and this will continue to apply to Omnitrope and Tev-Tropin. Omnitrope and Tev-Tropin do not require step therapy, while all other growth hormone products do.

Since growth hormone products are considered interchangeable, in early April, Harvard Pilgrim will notify members who use a non-preferred product that Omnitrope is now available for a lower copay. Because there is currently a shortage of Tev-Tropin, our member outreach will not encourage use of this medication.

In addition, one of Harvard Pilgrim’s specialty pharmacy vendors, Accredo, will contact prescribers of non-preferred growth hormone products to inform them that their patients can reduce their copay by switching to Omnitrope. In light of the Tev-Tropin shortage, Accredo will also contact prescribers of Tev-Tropin to notify them that any patients can switch to Omnitrope if they are having trouble obtaining Tev-Tropin.

To obtain prior authorization for growth hormone products, please complete the appropriate Medication Request Form and fax back to MedImpact Healthcare Systems at 888-807-6643.

Email this article to a colleague   

Receive Network Matters by e-mail

Network Matters Archives

Download printer-friendly version


The Affordable Care Act and Risk Adjustment


Spine Management and Prior Authorization

Medical Policy for Allergy Immunotherapy

Medical Policy for IgG Allergy Testing

Tier Change for Omnitrope and Tev-Tropin

Zostavax Now Available at Retail Pharmacies

P&T Committee Updates

Specialty Pharmacy Updates

Routine Screening for PTSD


Notifying Harvard Pilgrim of Provider Changes

CMS 1500 (08/05) Form Rejected After June 15


Eric H. Schultz,
President and Chief Executive Officer

Richard Weisblatt PhD,
Senior Vice President, Provider Network

Annmarie Dadoly,

Kristin Edmonston,
Production Coordinator